Royalty Pharma plc (NASDAQ:RPRX) has been receiving significant attention from institutional investors who hold approximately 70% of the company's shares. Its stocks are retaining a
Buy rating from analysts, largely based on the company's sustainable growth. The firm recently declared a quarterly dividend of $0.21, following the announcement of a
fourth-quarter dividend for 2024. Significant acquisitions of its shares were noted from players such as Dimensional Fund Advisors LP and Lighthouse Investment Partners LLC. The stock appears to be a popular choice among shareholders seeking big potential upside as per hedge fund estimates. Yet, some analysts indicate ambiguous financials, leaving doubts about the momentum of the stock. Recent transactions have seen insiders selling off US$44m of shares, adding to the uncertainty. Notwithstanding, Royalty Pharma entered a deal with
Ascendis Pharma, boosting the former's footprint in the sector and retained a
Buy rating on sustainable growth.
Annual Earnings per Share (EPS) in 2023 far outstripped the figures for 2022, and even though it lagged behind the 2024 second-quarter expectations, EPS exceeded estimates.
Royalty Pharma Stocks News Analytics from Mon, 18 Jun 2018 07:00:00 GMT to Sat, 12 Oct 2024 12:34:26 GMT -
Rating 5
- Innovation -4
- Information 8
- Rumor -2
